Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a Bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema (HAE) attacks in patients with confirmed HAE types I and II.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products sourced from the European Union market to meet global therapeutic needs.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

Hereditary angioedema type I: rapid reduction of swelling during acute attacks. Hereditary angioedema type II: rapid reduction of swelling during acute attacks. Acute hereditary angioedema in adults: shortens duration and severity of symptoms.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: mild local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head pain. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling. - Urticaria: hives appearing after administration. - Thrombocytopenia: low platelet count observed in rare cases.

Before initiating therapy, consider the following precautions: - Confirm diagnosis: ensure the patient has hereditary angioedema before use. - Monitor for hypersensitivity: watch for signs of allergic reaction after injection. - Cardiovascular caution: use carefully in patients with known heart disease or unstable blood pressure. - Avoid in known allergy: do not administer to individuals with hypersensitivity to icatibant or any excipients. - Pregnancy and lactation: safety not established; weigh risks and benefits before prescribing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence bradykinin or blood pressure.

Major Interactions (Avoid): - ACE inhibitors: increase bradykinin levels, raising risk of angioedema. - Other bradykinin B2 antagonists: additive antagonism may lead to excessive blockade. - Renin‑angiotensin system blockers: potential for enhanced hypotensive effects.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of hypersensitivity. - Corticosteroids: could alter immune response, requiring observation. - Concurrent injectable biologics: may increase incidence of injection‑site reactions.